Company Overview and News

KLCI gains 0.39%, tracks regional markets

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.39% at mid-morning today, lifted by index-linked blue chips and tracking the steady regional markets.
7052 7036 5681 BATS 4162 3034 1481 5014 6033 0152 1783 PNADF 5225 SGPBY 5209 2216 2739 MYPRY Q0F IHHHF PNAGF

Stock With Momentum: DGB Asia

2018-07-19 theedgemarkets
TRADING in DGB Asia Bhd (fundamental: 1.5/3, valuation: 0.6/3) shares triggered our proprietary momentum algorithm yesterday for the fourth time this year.

The Week Ahead: Eyes on Trump-Kim rendezvous, FOMC hike, full Cabinet line-up and World Cup 2018

2018-06-11 theedgemarkets
The world will be watching two of the greatest shows this week — the momentous meeting between US President Donald Trump and North Korean leader Kim Jong-un at the Capella Hotel in Singapore on June 12, and the kick-off of the 2018 Fifa World Cup in Moscow on Thursday, just ahead of the Hari Raya celebrations on Friday.
9717 5216 1201 3921 0091 CPICQ FUTR 5085 0151 8311 0152 LIIHF

Trading ideas: Puncak Niaga, F&N, DGB Asia

KUALA LUMPUR:JF Apex Research expects Puncak Niaga Holdings Bhd , Fraser & Neave Holdings Bhd (F&N) and DGB Asia Bhd to generate trading interest following its latest corporate news.
6807 0152

KL shares weak at opening

2018-03-20 themalaymailonline
KUALA LUMPUR, March 20 — Shares on Bursa Malaysia opened lower today with investors staying on the sidelines ahead of the US Federal Reserve's two-day monetary policy meeting mid-week.
PBLOF 5270 1295 BSMAF 0152 1818

Bursa stays negative at mid-afternoon

2018-03-14 themalaymailonline
KUALA LUMPUR, March 14 — Bursa Malaysia remained in the red at mid-afternoon today as traders immersed in profit-taking activities, taking the cue from yesterday's close on a positive note, dealers said.
PBLOF 5225 1295 Q0F BSMAF IHHHF HIPEF 2097 0152 1818 5199

Bursa ends lower on rampant profit-taking

2018-03-14 themalaymailonline
KUALA LUMPUR, March 14 — Bursa Malaysia closed lower today, echoing global and regional equity performances on rampant profit-taking, leaving the indices in the red throughout the day, dealers said.
5238 PNADF PBLOF 1295 BSMAF 5025 PNAGF 6033 0152 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...